Related by context. All words. (Click for frequent words.) 65 Pivotal Trial 63 TAXUS ATLAS 62 Randomized Evaluation 61 Refractory Angina 61 SPIRIT FIRST 61 Acute Ischemic Stroke 60 Phase III Clinical Trial 60 Pivotal Phase III 60 multicenter randomized controlled 60 Long Lesion 60 ENDEAVOR IV 60 CUSTOM III 60 Phase III Psoriasis 60 EVEREST II 59 Randomized controlled 59 Phase #b/#a clinical 59 fosbretabulin 59 National Emphysema Treatment 59 randomized Phase IIb 59 Pivotal Phase 58 Acute Decompensated Heart Failure 58 Pivotal Clinical Trial 58 GORE TAG Device 58 Phase IIIb 58 ABSORB trial 58 TAXUS TM 58 Randomized Study 58 Eluting Stent 58 Xelox 58 TM Drug Eluting 58 EXPLORE Xa 58 Feasibility Trial 57 PERSEUS 57 Catheter Ablation 57 phase IIb clinical 57 Multicenter Automatic Defibrillator Implantation 57 TAXUS Liberté stent 57 Multicenter Randomized 57 ENDEAVOR III 57 Phase III Trial 57 Phase Ib clinical 57 PREVENT IV 57 Arimidex Tamoxifen Alone 57 pain palliation 57 Severe Sepsis 57 DAPT 57 Phase 1a clinical 57 ENDEAVOR II 57 Randomised 57 Prospective Randomized 57 Carotid 57 multicentre randomized controlled 57 phase IIa clinical 57 phase III ACCLAIM 56 Val HeFT 56 randomized controlled multicenter 56 Augment Injectable 56 TG MV 56 LUMINATE 56 PSMA ADC 56 VESTASYNC 56 Embolic Protection Device 56 multicenter Phase III 56 phase IIa 56 ZACTIMA 56 Adjuvant Treatment 56 EchoCRT 56 Vascugel 56 PFO migraine 56 multicenter randomized placebo controlled 56 BRIM2 56 Rheos System 56 CBLC# 56 Randomized Clinical Trial 56 MADIT II 56 Efficacy Trial 56 Medtronic CoreValve ® 56 placebo controlled clinical 56 Pivotal Trials 56 VADT 55 multicenter Phase II 55 Phase 2b Clinical Trial 55 Phase IIb III 55 Myocardial Infarction Study 55 EURIDIS 55 Phase IIIb clinical 55 PreCISe 55 Patients Treated With 55 Phase 1a 55 MEND CABG 55 SPIRIT IV 55 Initiate Phase 55 multicenter clinical 55 recurrent glioma 55 drug eluting stent DES 55 Clinical Trial Evaluating 55 catheter occlusion 55 Hormone Refractory Prostate Cancer 55 randomized controlled clinical 55 GEM OS2 55 Clinical Trial Results 55 DuraHeart TM 55 Phase Ib II 55 BrachySil TM 55 Anticancer Drug 55 multicenter randomized clinical 55 Alfimeprase 55 Intervention Effectiveness 55 Phase III Clinical Trials 55 Multicenter 55 Intravitreal 55 Oral Fingolimod 55 prospective multicenter randomized 55 Endurant 55 Aortic Valve 55 DuraHeart 55 Medtronic CoreValve 55 GEM OS1 55 Endarterectomy 55 assessing T DM1 55 Lung Cancer Screening 55 Completes Enrollment 55 Phase III HEAT 55 Aneurysm Repair 55 drug eluting coronary stent 55 RE MODEL 54 Phase 2b kidney transplant 54 prospective multicenter 54 Prolongs Survival 54 Amrubicin 54 TAXUS V 54 Edwards SAPIEN valve 54 Phase 2b Study 54 ToGA 54 Novo TTF 54 Adjuvant Breast Cancer 54 multicentre randomized 54 Phase IIb Clinical Trial 54 pivotal bioequivalence 54 CLARITY study 54 Improves Outcomes 54 Edge STudy 54 Phase Ib IIa 54 budesonide foam 54 registrational Phase 54 Plasmin 54 Phase III psoriasis 54 riociguat 54 Emboshield 54 CHAMPION PCI 54 eluting stent 54 Stabilimax NZ 54 Dacogen decitabine 54 CURRENT OASIS 7 54 Thorough QT 54 Initiated Phase 54 APEX PD 54 randomized blinded 54 Universal Flu Vaccine 54 NeuroFlo 54 PROMUS Element Stent 54 Luveniq 54 RE LY ® 54 Phase IIA 54 VITAL Trial 54 clevidipine 54 Tacrolimus 54 CARE HF 54 Endeavor drug eluting 54 Spine Patient Outcomes 54 CCX# B 54 NSABP B 54 Randomized Double Blind 54 TAXUS Liberte 54 placebo controlled Phase III 54 TAXUS Element Paclitaxel Eluting 54 RSD# oral 54 II Clinical Trial 54 SUTENT ® 54 Anturol TM 54 transfemoral 53 Phase IIB 53 thorough QT 53 Vascugel ® 53 liposomal formulation 53 ONTARGET R 53 Phase Ib IIa clinical 53 Prostate AdenoCarcinoma Treatment 53 Recurrent Glioblastoma 53 TASKi3 53 Safinamide 53 Motesanib 53 GAMMAGARD 53 azilsartan medoxomil 53 double blinded randomized 53 Radiofrequency Ablation RFA 53 SEPET TM 53 OHR/AVR# 53 phase IIb III 53 Clinical Study 53 treatment naive genotype 53 saphenous vein graft 53 relapsing multiple sclerosis 53 CLOTS 53 phase Ib clinical 53 paclitaxel poliglumex 53 multicenter prospective 53 Delcath Phase III 53 Aeroquin 53 BST CarGel R 53 TAXUS Stent 53 ADVANCE PD 53 Cloretazine ® 53 Ceplene/IL-2 53 confirmatory clinical 53 Ereska 53 Trial Evaluating 53 Melphalan 53 Placebo Controlled Trial 53 MADIT 53 ENESTnd 53 Combination REOLYSIN R 53 PREOS R 53 recurrent malignant glioma 53 phase Ib 53 Improves Survival 53 Shows Promise Against 53 investigational protease inhibitor 53 MedPulser 53 IFN α 53 Cypher Stent 53 carotid stent 53 Raloxifene Evaluation MORE 53 CATIE AD 53 Lung Cancer Trial 53 IMPACT DCM clinical 53 Inhibits Growth 53 Initiate Phase III 53 subconjunctival injection 53 melphalan prednisone 53 Phase 1b Clinical Trial 53 dose escalation phase 53 Granted Orphan Drug 53 prospective randomized multicenter 53 HuMax EGFr 52 Randomized Double blind 52 galiximab 52 Non Inferiority 52 CRLX# 52 CentriMag 52 myoblast therapy 52 SUPERA stent 52 RhuDex 52 Pharmacokinetic studies 52 RE COVER 52 Zemplar Capsules 52 Sirolimus eluting 52 thrombus aspiration 52 doxorubicin docetaxel 52 ThermoDox R 52 blinded randomized placebo controlled 52 Kamada AAT 52 Kahalalide F 52 blinded randomized 52 REVEAL Registry 52 Dose Ranging Study 52 Parathyroid Hormone 52 Randomized Phase II 52 randomized multicenter Phase III 52 Intervention Trial 52 CVBT #H 52 acute PAO 52 NSABP 52 TAXUS ATLAS Small 52 receptor tyrosine kinase inhibitor 52 sirolimus eluting stents 52 tanespimycin 52 candidate CRLX# 52 Cloretazine R 52 nonrandomized 52 EOquin TM 52 Circulatory Support 52 Ascendra 52 Pre RELAX AHF 52 including eniluracil ADH 52 MEND CABG II 52 MYDICAR 52 Phase 1b clinical 52 acyclovir Lauriad R 52 Prostate Cancer Prevention 52 Ovarian Cancer Diagnostic 52 Ischemia 52 placebo controlled Phase 52 Subgroup analysis 52 masked placebo controlled 52 BioSTAR R 52 everolimus eluting stents 52 Confirmatory Phase 52 Cholesterol Levels SPARCL 52 Hsp# Inhibitor 52 Mipomersen 52 TAXUS IV 52 Interferon Alpha 52 EmbraceAC 52 NCIC CTG 52 Neupogen ® 52 Phase IIIb study 52 Initiate Phase II 52 CIPN 52 NP2 Enkephalin 52 ONTARGET 52 Fontan procedure 52 ENGAGE AF TIMI 52 RE LY 52 Long Term Efficacy 52 CIMZIA ™ 52 XIENCE V PROMUS Stent 52 trials RCTs 52 IMPACT DCM 52 Sibutramine Cardiovascular Outcomes 52 Pharmacokinetic Study 52 ataluren 52 Demonstrates Efficacy 52 bioabsorbable stent 52 pharmacokinetic PK study 52 rotary VAD 52 randomized controlled Phase 52 Initiates Phase III 52 ACCORD Lipid 52 volociximab 52 YONDELIS 52 Pooled Analysis 52 Cethromycin 52 RELIANT Trial 51 Vascular Wrap 51 Capesaris 51 CCX# 51 TAXUS VI 51 Advanced Heart Failure 51 CLARITY TIMI 51 Cinacalcet HCl 51 daily subcutaneous injections 51 COR Diabetes 51 DASISION 51 Litx 51 RHEO 51 TOLAMBA 51 Self Expanding Stent 51 BrachySil ™ 51 dose escalation clinical 51 MYDICAR ® 51 #:# randomization 51 novel oral anticoagulant 51 Phase III Pivotal Trial 51 randomized multicentre 51 randomized multicenter 51 AIR2 Trial 51 Phase #b/#a 51 Subcutaneous 51 Phase IIa trials 51 CAMMS# 51 RECORD1 51 Multikine ® 51 laquinimod 51 Catena ® 51 noninferior 51 Archexin 51 dirucotide MBP# 51 XIENCE V stent 51 MAGE A3 ASCI 51 cannabinor 51 ILUVIEN 51 trastuzumab DM1 T DM1 51 saphenous vein grafts 51 Alvesco R 51 ancrod 51 MIST II 51 E1 INT TM 51 Teva Provides Update 51 Taxus Liberte 51 Phase 1b clinical trials 51 sunitinib malate 51 Drug Fails 51 Polyp Prevention Trial 51 HALO# [002] 51 TMC# C# 51 lomitapide 51 BRIM3 51 transapical 51 BCIRG 51 IABP 51 Novacor II 51 double blinded placebo 51 vemurafenib 51 IIa trials 51 Lung Cancer Drug 51 phase IIb trial 51 Phase IIb clinical trials 51 HCV RESPOND 2 51 Drug Shows Promise 51 multicentre 51 VNP#M 51 NVA# 51 Mycophenolate Mofetil 51 reteplase 51 LUVENIQ 51 refractory prostate cancer 51 Dose escalation 51 HCV SPRINT 51 CALGB # [002] 51 direct thrombin inhibitors 51 Phase IIB clinical 51 davunetide intranasal AL 51 CEQ# 51 MADIT CRT 51 Fabry Disease 51 Traficet EN 51 confirmatory Phase 51 CA4P 51 ticagrelor Brilinta 51 UPLYSO 51 Phase III placebo controlled 51 intravenous dosing 51 Controlled Study 51 XL# SAR# 51 NDA Submission 51 eplerenone 51 HGS# 51 AVADO 50 preclinical efficacy 50 Phase Ib study 50 canakinumab 50 MKC# MKC# PP 50 rFactor XIII 50 OLYMPIA registry 50 vidofludimus 50 TBC# 50 neratinib 50 biventricular 50 ACTIVE W 50 Phase III registrational 50 Clinical Antipsychotic Trials 50 Investigational Device Exemption IDE 50 Spheramine 50 Phase 2a clinical 50 phase IIb 50 ZYBRESTAT fosbretabulin 50 rALLy 50 SERCA2a 50 Confirms Efficacy 50 Randomized Trials 50 Aflibercept 50 Phase 1b trial 50 Aplidin R 50 Cloretazine 50 DEEP AF 50 multicenter clinical trials 50 Aplidin 50 Artery Disease 50 rALLy clinical trial 50 Rubicon Filter 50 Glufosfamide 50 Multiple Ascending Dose 50 motesanib 50 Resten NG 50 Xanafide 50 Myelodysplastic Syndrome MDS 50 Recurrent Prostate Cancer 50 AQ4N 50 Alequel 50 Malaria Vaccine 50 topically administered 50 Eluting 50 Nanocort 50 IND Application 50 GW# [003] 50 StemEx 50 Metricath Gemini 50 Phase III Trials 50 Cytochrome P# 50 Current Controlled Trials 50 Epanova 50 proteasome inhibitor bortezomib 50 REALITY Trial 50 ABSORB clinical 50 platelet inhibitor 50 Drug Candidate 50 Rotavirus Vaccine 50 Symadex 50 First Patient Dosed 50 Phase III VISTA 50 Phase #/#a 50 randomized discontinuation 50 Advagraf 50 prospective randomized controlled 50 SIMPADICO 50 Clinical Trial 50 Quinamed 50 Annuloplasty 50 Novacor LVAS 50 CIMZIA TM 50 Phase Ib 50 Simulect 50 Phase IIa trial 50 TB Vaccine 50 Placebo controlled 50 Pivotal Phase II 50 Sym# 50 Neovasc Reducer 50 bronchial thermoplasty 50 DSMB recommended 50 evaluating mipomersen 50 randomized multicenter trial 50 BAL# [002] 50 Allovectin 7 R 50 EndoTAG TM -1 50 cetrorelix pamoate 50 dosage regimens 50 PROTEGE 50 ISTODAX ® 50 BRAF inhibitor 50 Neo Bladder Augment 50 ADAGIO study 50 DUROS 50 TM Vascular Closure 50 Proves Effective 50 BrachySil 50 randomized #:#:# 50 fully bioabsorbable 50 Endoscopic Ablation System 50 Oral Insulin Capsule 50 albiglutide 50 neurologic progression 50 PRIMO CABG 50 HORIZONS AMI trial 50 IN.PACT 50 Levacor 50 PROMACTA 50 PROTECT AF 50 Placebo Controlled 50 Company proprietary INACTINE 50 everolimus eluting stent 50 CLL SLL 50 selective androgen receptor modulator 50 Exherin TM 50 trodusquemine 50 Zilver PTX 50 Saxagliptin 50 Xerecept 50 ZYBRESTAT TM 50 Endeavor DES 50 EMPHASIS HF trial 50 HDAC Inhibitor 50 docetaxel Taxotere ® 50 BioMatrix 50 Ophena 50 AZOR 50 AFRS TM 50 VersaFilm 50 ritonavir boosted 50 dose escalation Phase 50 demonstrated antitumor activity 50 Initiates Phase 2b 50 randomized Phase III 50 ClosureFAST catheter 50 DIABECELL R 50 Bioequivalence 50 inhaled AAT 50 SORT OUT III 50 novel VDA molecule 50 Left Atrial Appendage 49 relapsing remitting MS RRMS 49 Turbo Tandem 49 DuraHeart LVAS 49 eliglustat tartrate 49 Rheos 49 XYOTAX TM 49 generation rotary VAD 49 Stem Cell Treatment 49 CUSTOM II 49 Virulizin R 49 Sorafenib HCC Assessment 49 Autologous 49 Clinical Validation 49 phase IIb study 49 Ovarian Cancer Screening 49 sargramostim 49 STENT 49 Angiocept 49 SPIRIT III 49 randomizing patients 49 fallopian tube cancers 49 Combination Treatment 49 ALSYMPCA 49 neoadjuvant 49 CardioFit 49 Pimavanserin 49 RAV# 49 Enrolling Patients 49 adjuvant colon cancer 49 clinical pharmacology studies 49 ORAL Sync 49 CINTREDEKIN BESUDOTOX 49 IAP inhibitor 49 Convivia TM 49 NCT# ClinicalTrials.gov 49 BioSTAR ® 49 Tavocept 49 IIa Clinical Trial 49 myopic CNV 49 Zilver PTX stent 49 Amoxicillin PULSYS Phase III 49 Angiox R 49 CB2 selective receptor agonist 49 Periodontal Therapy 49 Gabapentin GR 49 multicenter phase 49 phase III SIMPADICO 49 ANCHOR trial 49 phase IIIb 49 Immunotherapeutic 49 XIENCE V Everolimus Eluting 49 NSABP C 49 Endovenous 49 NLX P# 49 Levacor TM 49 Phase IIb kidney transplant 49 cariprazine 49 Elocalcitol 49 mapatumumab 49 EVA 3S 49 Dalbavancin 49 Fibrillex TM 49 cluster randomized controlled 49 oral rivaroxaban 49 OBPM 49 Phase 2a Trial 49 PD2i CA 49 Aryplase 49 IIa clinical 49 Onrigin TM 49 Collategene 49 DXL# 49 Arthroplasty 49 Phase 2a trial 49 DU #b 49 Adjuvant Colon Cancer 49 DIABECELL ® 49 prospective randomized placebo 49 lorcaserin Phase 49 PANVAC VF 49 ularitide 49 TRO# 49 CURE AF 49 multicenter trials 49 Diabetic Ulcers 49 Long Term Outcomes 49 Cannabinor 49 unblinding 49 Reolysin 49 Shows Efficacy 49 Tolamba 49 RESOLUTE 49 axitinib 49 includes TOLAMBA TM 49 Phase Ia 49 PrevOnco ™ 49 AEGR 49 Phase III confirmatory 49 CryoPlasty 48 Factor VIIa 48 immunotherapeutic vaccine 48 randomized clinical 48 ONCONASE R 48 multicenter placebo controlled 48 Blinatumomab 48 placebo controlled randomized 48 Ceflatonin R 48 System LVAS 48 multicentre study 48 Fracture Intervention Trial 48 prospective observational 48 Clinical Outcomes Utilizing Revascularization 48 Vorapaxar 48 Allovectin 7 48 KRN# 48 Medidata Designer 48 pharmacodynamic PD 48 INGAP 48 Granulocyte Colony Stimulating Factor 48 RESOLUTE clinical 48 TELCYTA 48 Trovax 48 labial herpes 48 IIa trial 48 Phase III randomized controlled 48 IIb clinical trial 48 GRNVAC1 48 ERATO 48 Lixivaptan 48 Telintra 48 Onglyza saxagliptin 48 specified primary endpoint 48 prospective nonrandomized 48 edoxaban 48 Genous 48 opioid naive 48 intra arterial 48 Occluded 48 trastuzumab DM1 48 PF # [002] 48 LymphoStat B TM 48 ELIQUIS 48 nab paclitaxel 48 intravenous cyclophosphamide 48 number NCT# ClinicalTrials.gov 48 Ketotransdel 48 Dual Opioid 48 Thrombin 48 ROCKET AF 48 ENDEAVOR IV clinical 48 Prostate Cancer Vaccine 48 Onconase 48 Tanespimycin 48 Destination Therapy 48 Phase 2b 48 Phase Ib clinical trials 48 ATL/TV# 48 ganaxolone 48 Novacor R 48 PRESEPT study 48 AIR CF2 48 hypoxia activated prodrug 48 multicenter dose escalation 48 controlled multicenter 48 eosinophilic asthma 48 PARTNER Trial 48 RenalGuard System TM 48 immunomodulatory therapy 48 Protease Inhibitors 48 fidaxomicin Phase 3 48 SCD HeFT 48 CROSSER 48 myoblast 48 alvespimycin 48 Dendreon Provenge 48 chemoradiation therapy 48 inhaled treprostinil 48 temsirolimus 48 AQUAVAN R 48 Combo Stent 48 Phase 2b clinical trials 48 BETAS 48 GALNS 48 Orazol 48 WHIMS 48 CytoFabTM 48 HuMax CD4 48 ragweed allergy immunotherapeutic 48 Phase lll 48 BLP# Liposome Vaccine 48 oral ridaforolimus 48 Anticancer Activity 48 XIENCE 48 Palmaz stent 48 Amikacin Inhale 48 ANAVEX #-# [001] 48 Prostate Cancer Treatment 48 TACI Ig 48 Liposomal 48 Active Ulcerative Colitis 48 Irinotecan 48 tolevamer 48 randomized crossover 48 humanised monoclonal antibody 48 AOD# [002] 48 PrevOnco 48 CK # administered 48 bicifadine 48 confirmatory Phase III 48 Liprostin 48 Proxinium TM 48 Mylotarg 48 Albuferon Phase 48 APTIVUS 48 AVERROES 48 Nanobody 48 CorPath 48 ruxolitinib 48 PSN# [002] 48 Genzyme Synvisc 48 blinded placebo controlled 48 Abbokinase 48 REFLEX 48 Raloxifene STAR 48 Effectively Treats 48 Phase III 48 subanalysis 48 Vernakalant 48 Phase 2b study 48 Cotara 48 intratumoural 48 LVAS 48 SpideRX 48 Phase III randomized 48 administered subcutaneously 48 evaluating satraplatin plus 48 TURBO Booster 48 PRIMO CABG2 48 DiabeCell 48 European Sepsis Trial 47 multicenter randomized 47 IIa clinical trials 47 tipranavir 47 solanezumab 47 paricalcitol 47 Intervention Effectiveness CATIE 47 EDEMA3 47 vaccine Stimuvax 47 DiabeCell R 47 Biomarker Study 47 PLCO 47 unresectable HCC 47 MVax 47 locoregional disease 47 ARIKACE 47 abiraterone acetate 47 multicentre randomized double 47 olaparib 47 Vaxfectin TM 47 multikinase inhibitor 47 pharmacokinetic characteristics 47 AMD# [003] 47 pegylated liposomal doxorubicin 47 GetGoal Phase III 47 REMEDIAL II 47 anterior lumbar interbody fusion 47 Corlux 47 VentrAssist 47 Bendamustine 47 Phase IIa clinical 47 canagliflozin 47 masitinib 47 stated Michelle Berrey 47 GENASIS clinical 47 ADONIS 47 humanized monoclonal 47 Phase IIa 47 Raptiva ® 47 DiabeCell ® 47 Glucosamine Chondroitin Arthritis 47 Raptiva r 47 fenretinide 47 octreotide implant 47 bevacizumab Avastin ® 47 IMPACT DCM trial 47 modified REGENESIS Phase IIb 47 somatostatin analogue 47 rALLy trial 47 Trastuzumab DM1 47 metastatic hormone refractory 47 anastrazole 47 Antiarrhythmic 47 PEGylated interferon 47 acute ischemic stroke 47 SYN# 47 Nonclinical 47 randomized blinded placebo 47 Gliadel Wafer 47 Artificial Liver 47 AGGRASTAT R tirofiban hydrochloride 47 Lucanix 47 multicenter randomized double 47 CRRT 47 subcutaneously administered 47 Phase #/#a clinical 47 OncoVEX GM CSF 47 HuMax CD#b 47 recurrent metastatic 47 Dacogen injection 47 Aurora Kinase 47 solithromycin 47 liver transplant recipients 47 midstage trials 47 analgesic efficacy 47 LCP Tacro 47 XP #L 47 AIR CF1 47 Stabilimax 47 cortical stimulation 47 drug NP2 Enkephalin 47 LANTUS ® 47 Neuvenge 47 Acute Coronary Syndromes ACS 47 LibiGel Phase III 47 MIRCERA 47 TMC# [002] 47 epothilone KOS 47 uremic pruritus 47 darunavir r 47 DIABECELL 47 ASCT 47 PRECISE Trial 47 orally administered inhibitor 47 NovoSeven ® 47 ASCEND HF 47 multicenter Phase 47 dose cohorts 47 Scandinavian Cardiac Outcomes 47 OncoVex 47 lenalidomide Revlimid R 47 Arthritis Drug 47 ACV1 47 Diamyd ® 47 GSK# [001] 47 REGEN trial 47 OvaRex 47 Imprime PGG 47 Percutaneous Hepatic Perfusion PHP 47 ASSERT 47 docetaxel cisplatin 47 ISEL 47 Valtropin 47 midstage clinical trials 47 Percutaneous Transluminal Coronary Angioplasty 47 MICARDIS ® 47 dacetuzumab 47 OMP #M# 47 cathepsin K inhibitor 47 dosing cohorts 47 Levacor VAD 47 Reduce Cardiovascular 47 peripheral arterial 47 COMFORT II 47 ganetespib 47 oncolytic vaccine 47 romidepsin 47 RELIANT trial 47 blind multicenter 47 coflex 47 Phase IIb clinical 47 active comparator 47 lanreotide 47 GSK# [002] 47 tramiprosate Alzhemed TM 47 TRX1 47 Troxatyl 47 Oxygent 46 dose escalation 46 designated HVTN 46 Autologous Stem Cell 46 Vacc 4x 46 confirmatory Phase 3 46 PEARL SC 46 anecortave acetate 46 FlowCardia 46 tezampanel NGX# 46 CCR5 inhibitor 46 trastuzumab emtansine T DM1 46 FOR FURTHER INFORMATION ABOUT 46 FVIIa 46 Cinquil 46 NO# [002] 46 CALGB 46 Ventricular Assist Device VAD 46 somatostatin analog 46 TroVax ® 46 iSONEP 46 Prodarsan 46 Serada 46 PFO closure 46 ORMD 46 Asentar 46 tribulations Groenveld 46 anti CD3 46 GLP toxicology studies 46 PROCHYMAL 46 HF ACTION 46 pertuzumab 46 Increlex R 46 SIR Spheres 46 phase III isavuconazole 46 TransMID 46 WHI Dietary Modification 46 SYMMETRY trial 46 metastatic RCC 46 plerixafor 46 Brinavess 46 Huggins Cams Time 46 Mimpara 46 ORBIT II 46 Cloretazine R VNP#M 46 GRN# 46 MYTHOS trial 46 Zyclara 46 Febuxostat 46 AE# vaccine 46 Tolerability Study 46 SCENESSE ®